Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States

With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS research and human retroviruses 2021-11, Vol.37 (11), p.852-861
Hauptverfasser: Mounzer, Karam, Brunet, Laurence, Hsu, Ricky, Fusco, Jennifer, Vannappagari, Vani, Henegar, Cassidy, van Wyk, Jean, Crawford, Melissa, Lo, Janet, Fusco, Gregory
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 861
container_issue 11
container_start_page 852
container_title AIDS research and human retroviruses
container_volume 37
creator Mounzer, Karam
Brunet, Laurence
Hsu, Ricky
Fusco, Jennifer
Vannappagari, Vani
Henegar, Cassidy
van Wyk, Jean
Crawford, Melissa
Lo, Janet
Fusco, Gregory
description With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, virologically suppressed PLWH. ART-experienced, virologically suppressed PLWH ≥18 years of age in the Observational Pharmacoepidemiology Research and Analysis (OPERA) cohort were included for analysis if prescribed a new regimen containing one of the following core agents: dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or boosted darunavir (bDRV), for the first time between August 1, 2013 and December 31, 2017. Multivariable linear regression was used to assess the association between regimen and mean changes in BMI at 6, 12, and 24 months after switch. In unadjusted analyses, BMI increases ranged from 0.30 kg/m2 (bDRV) to 0.83 kg/m2 (RPV) at 24 months following switch, but gains were observed with every regimen. In adjusted analyses, compared to DTG, only bDRV was associated with a smaller increase in BMI at all time points, while EVG/c and RAL were associated with smaller increases in BMI at 6 months only. Overall, results were consistent in analyses stratified by baseline BMI category. BMI increases were relatively small but followed an upward trend over time in this cohort of treatment-experienced, suppressed PLWH. Gains were attenuated with a longer period of follow-up. BMI gains did not differ by regimens, except for bDRV regimens, which were consistently associated with smaller BMI increases than DTG.
doi_str_mv 10.1089/aid.2020.0287
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2528814796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2593670379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-c6af540117e5e1ef4634504b9feae914e0246188fefa11716d04bf0da4a37e203</originalsourceid><addsrcrecordid>eNpdkc1u2zAQhImgAeKmOeZOoJceKnf5I4k8ukbSGHDRIE5yFRhpZTOQSZWk0_iV-pSlmp56WmDn29kBhpBLBnMGSn8xtptz4DAHruoTMmNasEJJKN-RGSilC865PiPvY3wGAM15OSO_lzvjthipdfSr7470u4mRrlyHr3QRo2-tSdjRXzbt6MIlGzAF_2KDGegdbu0eHd1ksc3q3rstvQ9oUt6m4up1xGDRtdh9po82-MFvbWuG4Ug3h3EMGGM2vkU_DkjX9sXm679vblaPU5q0Q_rg7PR9k3KI-IGc9maIePFvnpOH66v75U2x_vFttVysi1aIOhVtZfpSAmM1lsiwl5WQJcgn3aNBzSQClxVTqsfeZIhVXRZ76Iw0okYO4px8evMdg_95wJiavY0tDoNx6A-x4SVXislaVxn9-B_67A_B5XSZ0qKqQdQ6U8Ub1QYfY8C-GYPdm3BsGDRTc01urpmaa6bmxB_XE44i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2593670379</pqid></control><display><type>article</type><title>Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States</title><source>Alma/SFX Local Collection</source><creator>Mounzer, Karam ; Brunet, Laurence ; Hsu, Ricky ; Fusco, Jennifer ; Vannappagari, Vani ; Henegar, Cassidy ; van Wyk, Jean ; Crawford, Melissa ; Lo, Janet ; Fusco, Gregory</creator><creatorcontrib>Mounzer, Karam ; Brunet, Laurence ; Hsu, Ricky ; Fusco, Jennifer ; Vannappagari, Vani ; Henegar, Cassidy ; van Wyk, Jean ; Crawford, Melissa ; Lo, Janet ; Fusco, Gregory</creatorcontrib><description>With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, virologically suppressed PLWH. ART-experienced, virologically suppressed PLWH ≥18 years of age in the Observational Pharmacoepidemiology Research and Analysis (OPERA) cohort were included for analysis if prescribed a new regimen containing one of the following core agents: dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or boosted darunavir (bDRV), for the first time between August 1, 2013 and December 31, 2017. Multivariable linear regression was used to assess the association between regimen and mean changes in BMI at 6, 12, and 24 months after switch. In unadjusted analyses, BMI increases ranged from 0.30 kg/m2 (bDRV) to 0.83 kg/m2 (RPV) at 24 months following switch, but gains were observed with every regimen. In adjusted analyses, compared to DTG, only bDRV was associated with a smaller increase in BMI at all time points, while EVG/c and RAL were associated with smaller increases in BMI at 6 months only. Overall, results were consistent in analyses stratified by baseline BMI category. BMI increases were relatively small but followed an upward trend over time in this cohort of treatment-experienced, suppressed PLWH. Gains were attenuated with a longer period of follow-up. BMI gains did not differ by regimens, except for bDRV regimens, which were consistently associated with smaller BMI increases than DTG.</description><identifier>ISSN: 0889-2229</identifier><identifier>EISSN: 1931-8405</identifier><identifier>DOI: 10.1089/aid.2020.0287</identifier><language>eng</language><publisher>New Rochelle: Mary Ann Liebert, Inc</publisher><subject>AIDS/HIV ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; Body mass ; Body mass index ; Body size ; Body weight gain ; HIV ; Human immunodeficiency virus</subject><ispartof>AIDS research and human retroviruses, 2021-11, Vol.37 (11), p.852-861</ispartof><rights>Copyright Mary Ann Liebert, Inc. Nov 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-c6af540117e5e1ef4634504b9feae914e0246188fefa11716d04bf0da4a37e203</citedby><cites>FETCH-LOGICAL-c337t-c6af540117e5e1ef4634504b9feae914e0246188fefa11716d04bf0da4a37e203</cites><orcidid>0000-0001-8467-4835 ; 0000-0003-1556-811X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Mounzer, Karam</creatorcontrib><creatorcontrib>Brunet, Laurence</creatorcontrib><creatorcontrib>Hsu, Ricky</creatorcontrib><creatorcontrib>Fusco, Jennifer</creatorcontrib><creatorcontrib>Vannappagari, Vani</creatorcontrib><creatorcontrib>Henegar, Cassidy</creatorcontrib><creatorcontrib>van Wyk, Jean</creatorcontrib><creatorcontrib>Crawford, Melissa</creatorcontrib><creatorcontrib>Lo, Janet</creatorcontrib><creatorcontrib>Fusco, Gregory</creatorcontrib><title>Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States</title><title>AIDS research and human retroviruses</title><description>With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, virologically suppressed PLWH. ART-experienced, virologically suppressed PLWH ≥18 years of age in the Observational Pharmacoepidemiology Research and Analysis (OPERA) cohort were included for analysis if prescribed a new regimen containing one of the following core agents: dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or boosted darunavir (bDRV), for the first time between August 1, 2013 and December 31, 2017. Multivariable linear regression was used to assess the association between regimen and mean changes in BMI at 6, 12, and 24 months after switch. In unadjusted analyses, BMI increases ranged from 0.30 kg/m2 (bDRV) to 0.83 kg/m2 (RPV) at 24 months following switch, but gains were observed with every regimen. In adjusted analyses, compared to DTG, only bDRV was associated with a smaller increase in BMI at all time points, while EVG/c and RAL were associated with smaller increases in BMI at 6 months only. Overall, results were consistent in analyses stratified by baseline BMI category. BMI increases were relatively small but followed an upward trend over time in this cohort of treatment-experienced, suppressed PLWH. Gains were attenuated with a longer period of follow-up. BMI gains did not differ by regimens, except for bDRV regimens, which were consistently associated with smaller BMI increases than DTG.</description><subject>AIDS/HIV</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Body weight gain</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><issn>0889-2229</issn><issn>1931-8405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkc1u2zAQhImgAeKmOeZOoJceKnf5I4k8ukbSGHDRIE5yFRhpZTOQSZWk0_iV-pSlmp56WmDn29kBhpBLBnMGSn8xtptz4DAHruoTMmNasEJJKN-RGSilC865PiPvY3wGAM15OSO_lzvjthipdfSr7470u4mRrlyHr3QRo2-tSdjRXzbt6MIlGzAF_2KDGegdbu0eHd1ksc3q3rstvQ9oUt6m4up1xGDRtdh9po82-MFvbWuG4Ug3h3EMGGM2vkU_DkjX9sXm679vblaPU5q0Q_rg7PR9k3KI-IGc9maIePFvnpOH66v75U2x_vFttVysi1aIOhVtZfpSAmM1lsiwl5WQJcgn3aNBzSQClxVTqsfeZIhVXRZ76Iw0okYO4px8evMdg_95wJiavY0tDoNx6A-x4SVXislaVxn9-B_67A_B5XSZ0qKqQdQ6U8Ub1QYfY8C-GYPdm3BsGDRTc01urpmaa6bmxB_XE44i</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Mounzer, Karam</creator><creator>Brunet, Laurence</creator><creator>Hsu, Ricky</creator><creator>Fusco, Jennifer</creator><creator>Vannappagari, Vani</creator><creator>Henegar, Cassidy</creator><creator>van Wyk, Jean</creator><creator>Crawford, Melissa</creator><creator>Lo, Janet</creator><creator>Fusco, Gregory</creator><general>Mary Ann Liebert, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8467-4835</orcidid><orcidid>https://orcid.org/0000-0003-1556-811X</orcidid></search><sort><creationdate>20211101</creationdate><title>Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States</title><author>Mounzer, Karam ; Brunet, Laurence ; Hsu, Ricky ; Fusco, Jennifer ; Vannappagari, Vani ; Henegar, Cassidy ; van Wyk, Jean ; Crawford, Melissa ; Lo, Janet ; Fusco, Gregory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-c6af540117e5e1ef4634504b9feae914e0246188fefa11716d04bf0da4a37e203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>AIDS/HIV</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Body weight gain</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mounzer, Karam</creatorcontrib><creatorcontrib>Brunet, Laurence</creatorcontrib><creatorcontrib>Hsu, Ricky</creatorcontrib><creatorcontrib>Fusco, Jennifer</creatorcontrib><creatorcontrib>Vannappagari, Vani</creatorcontrib><creatorcontrib>Henegar, Cassidy</creatorcontrib><creatorcontrib>van Wyk, Jean</creatorcontrib><creatorcontrib>Crawford, Melissa</creatorcontrib><creatorcontrib>Lo, Janet</creatorcontrib><creatorcontrib>Fusco, Gregory</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS research and human retroviruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mounzer, Karam</au><au>Brunet, Laurence</au><au>Hsu, Ricky</au><au>Fusco, Jennifer</au><au>Vannappagari, Vani</au><au>Henegar, Cassidy</au><au>van Wyk, Jean</au><au>Crawford, Melissa</au><au>Lo, Janet</au><au>Fusco, Gregory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States</atitle><jtitle>AIDS research and human retroviruses</jtitle><date>2021-11-01</date><risdate>2021</risdate><volume>37</volume><issue>11</issue><spage>852</spage><epage>861</epage><pages>852-861</pages><issn>0889-2229</issn><eissn>1931-8405</eissn><abstract>With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes in body mass index (BMI) among ART-experienced, virologically suppressed PLWH. ART-experienced, virologically suppressed PLWH ≥18 years of age in the Observational Pharmacoepidemiology Research and Analysis (OPERA) cohort were included for analysis if prescribed a new regimen containing one of the following core agents: dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), raltegravir (RAL), rilpivirine (RPV), or boosted darunavir (bDRV), for the first time between August 1, 2013 and December 31, 2017. Multivariable linear regression was used to assess the association between regimen and mean changes in BMI at 6, 12, and 24 months after switch. In unadjusted analyses, BMI increases ranged from 0.30 kg/m2 (bDRV) to 0.83 kg/m2 (RPV) at 24 months following switch, but gains were observed with every regimen. In adjusted analyses, compared to DTG, only bDRV was associated with a smaller increase in BMI at all time points, while EVG/c and RAL were associated with smaller increases in BMI at 6 months only. Overall, results were consistent in analyses stratified by baseline BMI category. BMI increases were relatively small but followed an upward trend over time in this cohort of treatment-experienced, suppressed PLWH. Gains were attenuated with a longer period of follow-up. BMI gains did not differ by regimens, except for bDRV regimens, which were consistently associated with smaller BMI increases than DTG.</abstract><cop>New Rochelle</cop><pub>Mary Ann Liebert, Inc</pub><doi>10.1089/aid.2020.0287</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8467-4835</orcidid><orcidid>https://orcid.org/0000-0003-1556-811X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0889-2229
ispartof AIDS research and human retroviruses, 2021-11, Vol.37 (11), p.852-861
issn 0889-2229
1931-8405
language eng
recordid cdi_proquest_miscellaneous_2528814796
source Alma/SFX Local Collection
subjects AIDS/HIV
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
Body mass
Body mass index
Body size
Body weight gain
HIV
Human immunodeficiency virus
title Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T00%3A13%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20Body%20Mass%20Index%20Associated%20with%20Antiretroviral%20Regimen%20Switch%20Among%20Treatment-Experienced,%20Virologically%20Suppressed%20People%20Living%20with%20HIV%20in%20the%20United%20States&rft.jtitle=AIDS%20research%20and%20human%20retroviruses&rft.au=Mounzer,%20Karam&rft.date=2021-11-01&rft.volume=37&rft.issue=11&rft.spage=852&rft.epage=861&rft.pages=852-861&rft.issn=0889-2229&rft.eissn=1931-8405&rft_id=info:doi/10.1089/aid.2020.0287&rft_dat=%3Cproquest_cross%3E2593670379%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2593670379&rft_id=info:pmid/&rfr_iscdi=true